Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co EBITDA per Employee

The EBITDA per Employee of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 18, 2026 is 72,586.12 CNY. In the previous year, EBITDA per Employee was 104,157.15 CNY — a change of -30.31% (lower).

EBITDA per Employee

72,586.12CNY

YoY

-30.31%

Last updated:

EBITDA per Employee of Harbin Pharmaceutical Group Co is 2025 72,586.12 CNY. EBITDA per Employee of Harbin Pharmaceutical Group Co was 2024 104,157.15 CNY. It decreases by -30.31% lower compared to the previous year.

The Harbin Pharmaceutical Group Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
66,312.67 CNY
Jan 1, 2019
42,303.47 CNY
Jan 1, 2020
-80,495.66 CNY
Jan 1, 2021
82,166.94 CNY
Jan 1, 2022
87,395.62 CNY
Jan 1, 2023
82,107.50 CNY
Jan 1, 2024
104,157.15 CNY
Jan 1, 2025
72,586.12 CNY
The Harbin Pharmaceutical Group Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
72,586.12CNY-30.31%
104,157.15CNY+26.85%
82,107.50CNY-6.05%
87,395.62CNY+6.36%
82,166.94CNY-202.08%
-80,495.66CNY-290.28%
42,303.47CNY-36.21%
66,312.67CNY-15.19%
78,189.95CNY-29.12%
110,309.44CNY+29.49%
85,185.37CNY+88.38%
45,220.68CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co Ltd is a pharmaceutical company based in Harbin, China, operating within the Health Care sector. The company engages in the research, development, manufacture, wholesale, and retail of pharmaceutical products. It has 10,064 employees, with its headquarters located in Harbin, Heilongjiang Province. Founded through an IPO on June 29, 1993, the company is listed on the Shanghai Stock Exchange under the ticker 600664.SS. Harbin Pharmaceutical Group's primary business activities include innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. The company operates across multiple sectors including antibiotics, over-the-counter drugs, health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. Its product portfolio features calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The company's website is https://www.hayao.com/, though the source description provided is untrusted and should not be relied upon for factual accuracy. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

EBITDA per Employee of Harbin Pharmaceutical Group Co is 72,586.12 CNY in 2025.

EBITDA per Employee of Harbin Pharmaceutical Group Co changed from 104,157.15 CNY to 72,586.12 CNY, representing a -30.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Harbin Pharmaceutical Group Co

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Harbin Pharmaceutical Group Co